Yazar "Cil, Barbaros" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    Effect of Use of Slow Release of Bone Morphogenetic Protein-2 and Transforming Growth Factor-Beta-2 in a Chitosan Gel Matrix on Cranial Bone Graft Survival in Experimental Cranial Critical Size Defect Model
    (Lippincott Williams & Wilkins, 2010) Canter, Halil Ibrahim; Vargel, Ibrahim; Korkusuz, Petek; Oner, Filiz; Gungorduk, Dilsad B.; Cil, Barbaros; Erk, Yucel
    Bone grafts, used for providing structural integrity of cranial vault remodeling, could not always integrate with the remaining bone structures. All efforts are focused on increasing incorporation of the applied bone grafts. Allografts were covered by chitosan so that slow release of bone morphogenetic protein-2 (BMP-2) and Transforming growth factor-beta-2 (TGF-beta-2) was achieved. Two hundred forty Wistar-Albino rats were distributed equally in 8 study groups. Study groups were designed as; defect group, autograft group, allograft group, chitosan group, allograft + chitosan, TGF-beta-2 group, BMP-2 group, and TGF-Beta-2 + BMP-2 group. Bone biopsies were obtained at second, eight, and 14th weeks. Bone regeneration was evaluated by morphologic studies detecting histologic bone healing and radiologic studies detecting bone density. Histologic findings were evaluated in 2 categories; tissue response to the implant and defect healing. Additionally, scanning electron microscopy for detailed morphologic evaluation was done. Bone density of the applied scaffold and the parietal bone at the same computed tomography section were measured in Hounsfield scale and this ratio was used for densitometry evaluations. Kruskal-Wallis test was used to analyze difference among groups according to the histologic and radiologic data. Pairwise comparisons were done using Mann-Whitney U test with Bonferroni correction. P < 0.05 was considered significant. In the morphologic studies, bone regeneration in BMP-2 group was found to be compatible with bone regeneration in gold standard autograft group and even better than it within 15 days. Chitosan is a biocompatible material. TGF-Beta-2 alone is not effective enough in bone regeneration; BMP-2 alone has a positive effect in every step of bone regeneration. Combining TGF-Beta-2 with BMP-2 does not lead to a better bone regeneration than using BMP-2 alone. A synergistic effect is not obtained by using these 2 factors together.
  • Küçük Resim
    Öğe
    Intraarterial polidocanol injection for the treatment of peripheral arteriovenous malformations
    (Springer, 2014) Ergun, Onur; Atli, Eray; Gulek, Bozkurt; Ciftci, Turkmen; Cil, Barbaros; Vargel, Ibrahim; Peynircioglu, Bora
    The purpose of this study was to investigate the efficacy and safety of intraarterial transcatheter administration of polidocanol as an alternative treatment for peripheral arteriovenous malformations (AVMs). The study comprised 10 patients (six males and four females) with a mean age of 28.8 years (range 8-52 years). All patients had trunk or extremity AVMs. Following the administration of general anesthesia or intravenous (IV) sedation, the patients underwent staged intraarterial polidocanol sclerotherapy with or without additional embolizations for their AVMs. The administration of polidocanol was executed by intraarterial infusion through a microcatheter or by direct percutaneous entry into the nidus under ultrasound guidance. A total of 19 sessions were accomplished in 10 patients. Polidocanol was used alone in six of the 19 sessions. In 13 sessions, polidocanol was used in combination with another agent (including n-butyl cyanoacrylate (NBCA), lipiodol, and ethanol) and/or coils. In two sessions, polidocanol was administered percutaneously under ultrasound guidance directly into the nidus documented by arteriography. No major complications occurred. Intraarterial transcatheter administration of polidocanol alone or in combination with other agents is a safe and effective alternative treatment for peripheral AVMs.
  • Küçük Resim
    Öğe
    Percutaneous management of peripheral vascular malformations: a single center experience
    (Turkish Soc Radiology, 2011) Turkbey, Baris; Peynircioglu, Bora; Arat, Anil; Canyigit, Murat; Ozer, Cigdem; Vargel, Ibrahim; Cil, Barbaros
    PURPOSE To review the therapeutic results of the combination of embolization and sclerotherapy, with or without surgery, in patients with peripheral vascular malformations (PVMs). MATERIALS AND METHODS A total of 40 patients (24 males and 16 females) with PVMs, who were treated via percutaneous embolization (transarterial [TA] versus direct puncture [DP]) and sclerotheraphy between March 2003 and September 2009, were included in this retrospective study. The mean age was 28 years (range, 6-66 years), and 9 patients (7 boys, 2 girls) were <= 18 years of age (range, 6-18 years). The 40 patients experienced 40 PVMs, of which 15 were localized to an upper extremity, 13 to a lower extremity, 7 to the axial body, and 5 to the pelvis. A total of 22 PVMs were high-flow, whereas 18 were low-flow. Indications for treatment included pain, swelling, extremity function loss, and cosmetic concerns. RESULTS A total of 85 embolization/sclerotheraphy sessions were performed (2.1 sessions per patient). For the 22 high-flow PVMs, 53 treatment sessions were completed (2.4 sessions per lesion). Of the high-flow PVMs, 10 were treated via embolization only (7 DP, 2 TA, 1 DP and TA), 5 via alcohol sclerotheraphy only (2 DP, 2 TA, 1 DP and TA) and 7 via a combination of embolization and sclerotheraphy (3 TA, 4 DP and TA). The agents of embolization and sclerotherapy were n-butyl cyanoacrylate (n=22 patients), Onyx (R) (n=12 patients), and alcohol (n=19 patients). A total of 18 low-flow PVMs were treated in 32 sessions (1.8 sessions per lesion), all via the direct puncture approach. Of the low-flow PVMs, 11 were treated with embolization only, 6 with sclerotheraphy only, and 1 with a combined approach. In 16 patients (6 high-flow versus 10 low-flow), after a mean of 2.1 sessions (range, 1-9 sessions), the percutaneously treated lesions were excised by surgery without any major complications. In the 24 patients who did not have surgery, the lesions significantly decreased in size and the complaints from these patients improved. In four patients, skin ulcerations were identified, two of these patients needed surgical grafting; whereas in one patient, sciatic nerve paralysis developed after trans-arterial embolization and recovery was achieved in six months. CONCLUSION Percutaneous treatment of PVMs by embolization and sclerotheraphy is a safe and effective method, provided that appropriate lesion classification and treatment agent selection are performed.